Curettage and cryosurgery – effective for the most common skin cancer
The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.
The combination of curettage and cryosurgery is a safe and effective treatment method for the most common form of skin cancer, basal cell carcinoma. A study from the… read more.
Pupils in the UK are not learning about potentially life-changing issues such as endometriosis, infertility, and miscarriage, according to a new study of curricula in science and in… read more.
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer… read more.
Recurrent cystitis (RC) is a frequent infection of the urinary tract and bladder, which is highly prevalent among postmenopausal women. Under healthy circumstances, the human vagina is home… read more.
Patients who feel low when having a cardiac device implanted are more likely to stop taking their heart medications than those without depression, according to research presented today… read more.
The Japan Pharmaceutical and Medical Devices Agency (PMDA) has approved Novartis’ Luxturna (voretigene neparvovec) for the treatment of inherited retinal dystrophies (IRDs) caused by biallelic RPE65 mutations. The… read more.
It’s estimated that around 25% of patients who have a cardiac arrest and receive cardiopulmonary resuscitation (CPR) in a normal hospital setting will survive. Those odds shoot up… read more.
GSK plc announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved an updated indication for Shingrix (Recombinant Zoster Vaccine, Adjuvanted – RZV) for the… read more.
Vitamin D supplements may reduce the risk of major cardiovascular events such as heart attacks among people aged over 60, finds a clinical trial published by The BMJ today. The… read more.
Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for… read more.
A $7 million study beginning this summer at Wake Forest University and Wake Forest University School of Medicine will help determine whether a combination of resistance training plus… read more.
While vaping provides a pathway to help smokers wanting to quit, for non-smokers it may be the first step on a pathway to taking up smoking, a new… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.